Streetbeat News

Earnings

PNW

Pinnacle West Capital projects its FY24 earnings per share (EPS) to be in the range of $4.60-$4.80, compared to the estimated $4.71. This forecast suggests a potential variance around the current analyst consensus, indicating a cautious but potentially optimistic outlook for the company's financial performance in the upcoming fiscal year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:00 pm

SHC

Sotera Health has reaffirmed its 2024 financial outlook, projecting net revenues and adjusted EBITDA growth of 4.0% to 6.0%. The company also forecasts an adjusted EPS of $0.67-$0.75, with an estimate of $0.71.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 11:59 am

PNW

Pinnacle West Capital reported Q1 2024 earnings of $0.15 per share, surpassing the $0.09 estimate, but its sales of $951.712M fell short of the $974.965M forecast, marking a 0.72% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 11:59 am

BTU

Peabody Energy (NYSE:BTU) reported Q1 earnings of $0.29 per share, missing the consensus estimate of $0.31, and sales of $983.60M, missing the estimate of $991.07M. This represents a significant decrease from the same period last year, with earnings down 82.74% and sales down 27.89%.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 11:58 am

ICFI

ICF International (NASDAQ:ICFI) reported Q1 earnings of $1.77 per share, surpassing the $1.46 estimate, a 24.65% increase from last year. Sales reached $494.44M, beating the $487.93M estimate, marking a 2.31% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 11:58 am

ACXP

Acurx Pharmaceuticals announced the presentation of its Phase 2 trial results for Ibezapolstat at the ESCMID Global 2024 Scientific Conference. This marks a significant milestone in the drug's development process, potentially impacting the company's stock as investors react to the trial outcomes.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 11:57 am

BRKR

Bruker Corporation's shares are trading lower due to a miss in their first-quarter revenue expectations.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 11:56 am

LUCD

PAVM

Lucid Diagnostics, a subsidiary of PAVmed, announced positive results from a National Cancer Institute-sponsored study on EsoGuard, a test for esophageal precancer. The study, published in the American Journal of Gastroenterology, showed EsoGuard's high sensitivity in detecting early precancer, particularly in short-segment cases. These results support Lucid's efforts to secure commercial and Medicare payer coverage for EsoGuard. The company plans to seek Medicare coverage based on this data, aiming to provide a noninvasive, efficient screening method for esophageal cancer prevention.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 11:54 am

MCS

Marcus (NYSE:MCS) reported Q1 2024 earnings with a GAAP EPS of $(0.38), meeting analyst expectations but marking a 22.58% decrease from the previous year. Sales reached $138.547M, slightly above the $137.582M forecast but showing a 9.02% decline year-over-year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 11:53 am

BCYC

Bicycle Therapeutics (NASDAQ:BCYC) reported Q1 2024 earnings with a GAAP EPS of $(0.62), surpassing the $(1.31) estimate, and sales of $19.530M, exceeding the $6.029M estimate. This represents significant improvements in both earnings and sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 11:53 am